Trial · NCT00499863
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Endpoint | Methylphenidate Transdermal System | -18.8 | Standard Error 1.01 | scores on a scale | |
| Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Endpoint | Placebo (PTS) | -8.8 | Standard Error 1.42 | scores on a scale | |
| Change From Baseline in the Conner's Parent Rating Scale-Revised (CPRS-R) Total Score at Endpoint | Methylphenidate Transdermal System | -20.9 | Standard Error 1.45 | scores on a scale | |
| Change From Baseline in the Conner's Parent Rating Scale-Revised (CPRS-R) Total Score at Endpoint | Placebo (PTS) | -7.5 | Standard Error 2.08 | scores on a scale | |
| Improvement in Clinical Global Impressions-Improvement (CGI-I) Score | Methylphenidate Transdermal System | 93 | Participants | ||
| Improvement in Clinical Global Impressions-Improvement (CGI-I) Score | Placebo (PTS) | 22 | Participants | ||
| Improvement in Parent Global Assessment (PGA) Score | Methylphenidate Transdermal System | 76 | Participants | ||
| Improvement in Parent Global Assessment (PGA) Score | Placebo (PTS) | 15 | Participants | ||
| Change From Baseline in Youth Quality of Life-research Version (YQOL-R) Total Score at Endpoint | Methylphenidate Transdermal System | 3.3 | Standard Error 1.06 | scores on a scale | |
| Change From Baseline in Youth Quality of Life-research Version (YQOL-R) Total Score at Endpoint | Placebo (PTS) | 1.3 | Standard Error 1.55 | scores on a scale | |
| Post Sleep Questionnaire (PSQ) Quality of Sleep | Methylphenidate Transdermal System | Very poor | 2 | Participants | |
| Post Sleep Questionnaire (PSQ) Quality of Sleep | Placebo (PTS) | Very poor | 2 | Participants | |
| Post Sleep Questionnaire (PSQ) Quality of Sleep | Methylphenidate Transdermal System | Poor | 14 | Participants | |
| Post Sleep Questionnaire (PSQ) Quality of Sleep | Placebo (PTS) | Poor | 7 | Participants | |
| Post Sleep Questionnaire (PSQ) Quality of Sleep | Methylphenidate Transdermal System | Average | 27 | Participants | |
| Post Sleep Questionnaire (PSQ) Quality of Sleep | Placebo (PTS) | Average | 13 | Participants | |
| Post Sleep Questionnaire (PSQ) Quality of Sleep | Methylphenidate Transdermal System | Good | 47 | Participants | |
| Post Sleep Questionnaire (PSQ) Quality of Sleep | Placebo (PTS) | Good | 18 | Participants | |
| Post Sleep Questionnaire (PSQ) Quality of Sleep | Methylphenidate Transdermal System | Very good | 31 | Participants | |
| Post Sleep Questionnaire (PSQ) Quality of Sleep | Placebo (PTS) | Very good | 18 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00499863/results